Around 5,000 Long Islanders, including those providing treatment to veterans and gang-vulnerable youths, will obtain free mental health training under a newly awarded federal grant, officials said.
Reported by Newsday 4 hours ago.
Feds to finance mental health training for thousands on Long Island
↧
↧
George H.W. Bush: Military personnel pay tribute to last presidential war hero
As the last in a line of presidential war heroes, George H.W. Bush is being remembered by military veterans and active duty military personnel as a fearless patriot who set the standard for public service.
Reported by FOXNews.com 2 hours ago.
↧
Sully, Bush’s Service Dog, Visits Casket in Capitol
As former President George Bush lay in state, his service dog, Sully, circled the casket in the Capitol Rotunda. Sully was accompanied by wounded veterans.
Reported by NYTimes.com 1 hour ago.
↧
Defence Secretary promises legal witch-hunt of Army veterans 'will end soon'
Gavin Williamson is expected to propose new laws to stop the ‘absolute tragedy’ of former British troops being pursued through the courts.
Reported by MailOnline 1 hour ago.
↧
Recent retirees Perez, Munoz adjusting to life after playing careers
Both long-time Concacaf veterans took part in Monday's Champions League draw after retiring in the last few months
Reported by Goal.com 45 minutes ago.
↧
↧
Defence Secretary promises legal witch-hunt of Army veterans 'will end soon'
Gavin Williamson is expected to propose new laws to stop the ‘absolute tragedy’ of former British troops being pursued through the courts.
Reported by MailOnline 22 hours ago.
↧
A City Solves Veteran Homelessness
Rockford, Ill., is one of the first cities to effectively end homelessness among veterans. Officials consider its programs a model for other cities.
Reported by Wall Street Journal 18 hours ago.
↧
Zimbabwe: Warring Veterans Urged to Close Ranks
[The Herald] The Zanu-PF national leadership has read the riot act to war veterans here over apparent lack of unity as evidenced by the existence of two leaders claiming to be chairpersons of the war veterans' association in the province.
Reported by allAfrica.com 15 hours ago.
↧
Delayed GI Bill checks caused veterans to be late on rent, school fees
Software at the VA couldn't keep up with changes implemented by the new Forever GI Bill in August, creating a backlog that affected college students, including hundreds on Long Island.
Reported by Newsday 12 hours ago.
↧
↧
Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis
- Clinically Meaningful Improvements in Portal Hypertension in High Risk Compensated Cirrhosis Patients -
*- Conference Call and Webcast Presentation at 8:30 a.m. ET Today -*
SAN DIEGO, Dec. 05, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced top-line results from the company’s Phase 2b ENCORE-PH clinical trial showing clinically meaningful treatment effects in compensated NASH cirrhosis patients at high risk of decompensation. The trial’s primary endpoint was change in mean hepatic venous pressure gradient (HVPG) from baseline to Week 24 in any of three emricasan dosing groups compared with placebo. In the overall trial population, changes in HVPG from baseline to Week 24 showed trends consistently favoring emricasan compared with placebo but did not meet the primary endpoint.
The total patient population was composed of two prespecified subgroups – patients with compensated NASH cirrhosis (201 of 263 patients, or 76%) and patients with early decompensated NASH cirrhosis (62 of 263 patients, or 24%). Steven J. Mento, Ph.D., President, Chief Executive Officer and co-founder of Conatus, said, “Based on previous discussions with regulators, we expect that separate registration trials would be needed in compensated and decompensated NASH cirrhosis. This trial purposely enrolled mostly compensated patients, and we are encouraged by the treatment effect shown in this population in these top-line results.”
In patients with compensated NASH cirrhosis, post hoc analyses demonstrated consistent improvements in mean HVPG at week 24 over baseline. In these same patients, clinically meaningful differences compared with placebo in mean HVPG at Week 24 were observed in a consistent pattern over multiple baseline HVPG cohorts from ≥13 mmHg through ≥17 mmHg. The magnitude of the improvement in mean HVPG generally increased as the baseline HVPG levels increased. Both the 25mg and 50mg active dose groups achieved a >10% improvement in mean HVPG compared with placebo in all HVPG cohorts from ≥13 mmHg through ≥17 mmHg, while placebo-treated patients showed increases in mean HVPG. The greatest improvement was observed in patients with a baseline HVPG of 16 mmHg or higher.
“Patients with compensated cirrhosis and severe portal hypertension, that is, with HVPG of 12 mmHg or higher, are at risk for decompensation, that is, they are at risk for developing complications such as variceal hemorrhage, hepatic encephalopathy and ascites that significantly decrease their quality of life and survival,” said Guadalupe Garcia-Tsao, M.D., Professor of Medicine in the Section of Digestive Diseases at Yale School of Medicine, Director of the Clinical and Translational Core at Yale Liver Center, Chief of the Section of Digestive Diseases at the Veterans Administration-Connecticut Health Care System, and the central reader for the HVPG tracings in the ENCORE-PH clinical trial. “We have recently shown that the risk of decompensation and death rises with progressive increases in HVPG. Conversely, reductions in HVPG as small as 1 mmHg can reduce the risk of decompensation or death. Post-hoc analyses from the ENCORE-PH trial showing that, compared to placebo, emricasan is associated with clinically meaningful incremental reductions in HVPG with worsening baseline HVPG levels, strongly suggest that emricasan has the potential of providing patient benefit.”
The high-risk subgroup of compensated patients with HVPG ≥16 mmHg at baseline showed a clinically meaningful ≥2-point improvement in mean HVPG compared with placebo in all three emricasan dosing groups. A favorable trend compared with placebo in responses predictive of clinical benefit (≥20% reduction in HVPG from baseline) was also observed in the total ≥12 mmHg compensated patient population with the greatest responses observed in the ≥16 mmHg cohort. The baseline HVPG ≥16 mmHg cohort resembles the patient population studied in the prior Portal Hypertension pilot study and again shows, now in a placebo-controlled trial, a clinically meaningful improvement in mean HVPG. In addition, HVPG of ≥16 mmHg predicts a higher risk of both clinical events and death^1.
“This trial evaluated the ability of emricasan to reduce HVPG in patients with cirrhosis due to NASH. Although the primary endpoint was not met, the data indicates an amelioration of portal pressures by emricasan,” said Arun Sanyal, M.B.B.S, M.D., Professor of Medicine, Physiology and Molecular Pathology at Virginia Commonwealth University School of Medicine, chair of the NIH NASH Clinical Research Network, and chair of the Liver Forum. “Not surprisingly, those with the highest HVPG had the greatest benefit and the trends in all groups on sensitivity analyses favored active therapy. Together, these suggest that the findings are real and support additional investigation of this compound for those with compensated cirrhosis due to NASH and high HVPG, i.e., the population at greatest risk of clinical decompensation for whom there are no alternate approved therapies.”
Consistent with safety results from 17 previously completed clinical trials, emricasan was generally well-tolerated in the ENCORE-PH clinical trial, and the overall safety profile was similar in the emricasan and placebo groups. Patients enrolled in the ENCORE-PH clinical trial are continuing treatment or placebo in a six-month extension period to evaluate longer term safety, liver function and clinical outcomes, and results on the extension are expected in mid-2019.
“We believe data from the ENCORE-PH clinical trial as well as data from our two ongoing ENCORE trials that will be available in 2019 will warrant future discussions with regulatory authorities regarding potential pivotal trials in patients with NASH and advanced liver disease,” said David T. Hagerty, M.D., Executive Vice President of Clinical Development at Conatus. “We are grateful to the NASH cirrhosis patients who participated unselfishly in the ENCORE-PH clinical trial, and to the principal investigators who treated them in compliance with a rigorous protocol. We also thank the clinical site support staffs and the site monitoring, data collection and analysis teams who maintained schedule integrity from launch through results.”
*Conference Call/Webcast/Presentation*
Conatus will host a conference call and webcast at 8:30 a.m. Eastern Time today, December 5, to discuss the ENCORE-PH top-line results. To access the conference call, please dial 877-312-5857 (domestic) or 970-315-0455 (international) at least five minutes prior to the start time and refer to conference ID 9356879. An associated presentation and live and archived audio webcast of the call will be available in the Investors section of the company’s website at www.conatuspharma.com.
*About Emricasan
*Emricasan is a first-in-class, orally active pan-caspase inhibitor designed to reduce the activity of enzymes that mediate inflammation and apoptosis. Conatus believes that by reducing the activity of these enzymes, caspase inhibitors have the potential to interrupt the progression of a variety of diseases. To date, emricasan has been studied in approximately 700 patients in 17 completed clinical trials across a broad range of liver diseases. In multiple Phase 2 clinical trials, emricasan has demonstrated clinically meaningful reductions in severe portal hypertension, improvements in measures of liver function, and evidence of an anti-fibrotic treatment effect, as well as rapid and sustained reductions in elevated levels of key biomarkers of inflammation and cell death, which play a role in the severity and progression of liver disease.
*About ENCORE-PH
*The randomized, double-blind ENCORE-PH Phase 2b clinical trial, initiated in the fourth quarter of 2016, enrolled 263 NASH patients with compensated or early decompensated liver cirrhosis and severe portal hypertension confirmed by HVPG of ≥12 mmHg at baseline. Patients were randomized 1:1:1:1 to receive 5 mg of emricasan, 25 mg of emricasan, 50 mg of emricasan, or placebo twice daily for 24 weeks. The trial was conducted at 75 U.S. and EU sites.
*About Emricasan Clinical Development
*ENCORE-PH is one of three randomized, double-blind, placebo-controlled Phase 2b clinical trials being conducted by Conatus in collaboration with Novartis, the EmricasaN, a Caspase inhibitOR, for Evaluation (ENCORE) trials, designed to evaluate emricasan in patients with fibrosis or cirrhosis caused by NASH. Extension of the ENCORE-PH trial as well as two additional ENCORE clinical trials are ongoing:
· ENCORE-PH (for Portal Hypertension) six-month extension, with 48-week liver function and clinical outcome results expected in mid-2019;
· ENCORE-NF (for NASH Fibrosis), initiated in the first quarter of 2016, in approximately 330 patients with NASH fibrosis, with top-line results expected in the first half of 2019; and· ENCORE-LF (for Liver Function), initiated in the second quarter of 2017, in approximately 210 patients with decompensated NASH cirrhosis, with top-line results expected in mid-2019.
*About Conatus Pharmaceuticals*
Conatus is a biotechnology company focused on the development of novel medicines to treat liver disease. In collaboration with Novartis, Conatus is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease. For additional information, please visit www.conatuspharma.com.
*Forward-Looking Statements**
*This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding: separate registration trials being needed in compensated and decompensated NASH cirrhosis; emricasan’s potential to provide clinical benefit; the timeline to announce results from the extension phase of the ENCORE-PH trial in mid-2019; the data from the ENCORE-PH, ENCORE-NF and ENCORE-LF trials warranting future discussions with regulatory authorities regarding pivotal trials; the timelines to announce results from the ongoing ENCORE clinical trials; and caspase inhibitors’ potential to interrupt the progression of a variety of diseases. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including: reported top-line results are based on preliminary analysis of key data and as a result, such top-line results may change following a more comprehensive review and may not accurately reflect the complete results of the clinical trial; Conatus’ ability to successfully enroll patients in and complete its ongoing clinical trials; Novartis continuing development and commercialization of emricasan; Conatus’ reliance on third parties to conduct its clinical trials, including the enrollment of patients, and manufacture its clinical drug supplies of emricasan; potential adverse side effects or other safety risks associated with emricasan that could delay or preclude its approval; results of future clinical trials of emricasan; and those risks described in Conatus’ prior press releases and in the periodic reports it files with the Securities and Exchange Commission. The events and circumstances reflected in Conatus’ forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, Conatus does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
^1 Berzigotti A et al. Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension. J Gastroenterol 2011. DOI: 10.1007/s00535-010-0360-z.
Turco L et al. Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis. J Hepatol 2018. DOI: 10.1016/j.jhep.2017.12.027.
*CONTACT:* Alan Engbring
Conatus Pharmaceuticals Inc.
(858) 376-2637
aengbring@conatuspharma.com Reported by GlobeNewswire 11 hours ago.
*- Conference Call and Webcast Presentation at 8:30 a.m. ET Today -*
SAN DIEGO, Dec. 05, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced top-line results from the company’s Phase 2b ENCORE-PH clinical trial showing clinically meaningful treatment effects in compensated NASH cirrhosis patients at high risk of decompensation. The trial’s primary endpoint was change in mean hepatic venous pressure gradient (HVPG) from baseline to Week 24 in any of three emricasan dosing groups compared with placebo. In the overall trial population, changes in HVPG from baseline to Week 24 showed trends consistently favoring emricasan compared with placebo but did not meet the primary endpoint.
The total patient population was composed of two prespecified subgroups – patients with compensated NASH cirrhosis (201 of 263 patients, or 76%) and patients with early decompensated NASH cirrhosis (62 of 263 patients, or 24%). Steven J. Mento, Ph.D., President, Chief Executive Officer and co-founder of Conatus, said, “Based on previous discussions with regulators, we expect that separate registration trials would be needed in compensated and decompensated NASH cirrhosis. This trial purposely enrolled mostly compensated patients, and we are encouraged by the treatment effect shown in this population in these top-line results.”
In patients with compensated NASH cirrhosis, post hoc analyses demonstrated consistent improvements in mean HVPG at week 24 over baseline. In these same patients, clinically meaningful differences compared with placebo in mean HVPG at Week 24 were observed in a consistent pattern over multiple baseline HVPG cohorts from ≥13 mmHg through ≥17 mmHg. The magnitude of the improvement in mean HVPG generally increased as the baseline HVPG levels increased. Both the 25mg and 50mg active dose groups achieved a >10% improvement in mean HVPG compared with placebo in all HVPG cohorts from ≥13 mmHg through ≥17 mmHg, while placebo-treated patients showed increases in mean HVPG. The greatest improvement was observed in patients with a baseline HVPG of 16 mmHg or higher.
“Patients with compensated cirrhosis and severe portal hypertension, that is, with HVPG of 12 mmHg or higher, are at risk for decompensation, that is, they are at risk for developing complications such as variceal hemorrhage, hepatic encephalopathy and ascites that significantly decrease their quality of life and survival,” said Guadalupe Garcia-Tsao, M.D., Professor of Medicine in the Section of Digestive Diseases at Yale School of Medicine, Director of the Clinical and Translational Core at Yale Liver Center, Chief of the Section of Digestive Diseases at the Veterans Administration-Connecticut Health Care System, and the central reader for the HVPG tracings in the ENCORE-PH clinical trial. “We have recently shown that the risk of decompensation and death rises with progressive increases in HVPG. Conversely, reductions in HVPG as small as 1 mmHg can reduce the risk of decompensation or death. Post-hoc analyses from the ENCORE-PH trial showing that, compared to placebo, emricasan is associated with clinically meaningful incremental reductions in HVPG with worsening baseline HVPG levels, strongly suggest that emricasan has the potential of providing patient benefit.”
The high-risk subgroup of compensated patients with HVPG ≥16 mmHg at baseline showed a clinically meaningful ≥2-point improvement in mean HVPG compared with placebo in all three emricasan dosing groups. A favorable trend compared with placebo in responses predictive of clinical benefit (≥20% reduction in HVPG from baseline) was also observed in the total ≥12 mmHg compensated patient population with the greatest responses observed in the ≥16 mmHg cohort. The baseline HVPG ≥16 mmHg cohort resembles the patient population studied in the prior Portal Hypertension pilot study and again shows, now in a placebo-controlled trial, a clinically meaningful improvement in mean HVPG. In addition, HVPG of ≥16 mmHg predicts a higher risk of both clinical events and death^1.
“This trial evaluated the ability of emricasan to reduce HVPG in patients with cirrhosis due to NASH. Although the primary endpoint was not met, the data indicates an amelioration of portal pressures by emricasan,” said Arun Sanyal, M.B.B.S, M.D., Professor of Medicine, Physiology and Molecular Pathology at Virginia Commonwealth University School of Medicine, chair of the NIH NASH Clinical Research Network, and chair of the Liver Forum. “Not surprisingly, those with the highest HVPG had the greatest benefit and the trends in all groups on sensitivity analyses favored active therapy. Together, these suggest that the findings are real and support additional investigation of this compound for those with compensated cirrhosis due to NASH and high HVPG, i.e., the population at greatest risk of clinical decompensation for whom there are no alternate approved therapies.”
Consistent with safety results from 17 previously completed clinical trials, emricasan was generally well-tolerated in the ENCORE-PH clinical trial, and the overall safety profile was similar in the emricasan and placebo groups. Patients enrolled in the ENCORE-PH clinical trial are continuing treatment or placebo in a six-month extension period to evaluate longer term safety, liver function and clinical outcomes, and results on the extension are expected in mid-2019.
“We believe data from the ENCORE-PH clinical trial as well as data from our two ongoing ENCORE trials that will be available in 2019 will warrant future discussions with regulatory authorities regarding potential pivotal trials in patients with NASH and advanced liver disease,” said David T. Hagerty, M.D., Executive Vice President of Clinical Development at Conatus. “We are grateful to the NASH cirrhosis patients who participated unselfishly in the ENCORE-PH clinical trial, and to the principal investigators who treated them in compliance with a rigorous protocol. We also thank the clinical site support staffs and the site monitoring, data collection and analysis teams who maintained schedule integrity from launch through results.”
*Conference Call/Webcast/Presentation*
Conatus will host a conference call and webcast at 8:30 a.m. Eastern Time today, December 5, to discuss the ENCORE-PH top-line results. To access the conference call, please dial 877-312-5857 (domestic) or 970-315-0455 (international) at least five minutes prior to the start time and refer to conference ID 9356879. An associated presentation and live and archived audio webcast of the call will be available in the Investors section of the company’s website at www.conatuspharma.com.
*About Emricasan
*Emricasan is a first-in-class, orally active pan-caspase inhibitor designed to reduce the activity of enzymes that mediate inflammation and apoptosis. Conatus believes that by reducing the activity of these enzymes, caspase inhibitors have the potential to interrupt the progression of a variety of diseases. To date, emricasan has been studied in approximately 700 patients in 17 completed clinical trials across a broad range of liver diseases. In multiple Phase 2 clinical trials, emricasan has demonstrated clinically meaningful reductions in severe portal hypertension, improvements in measures of liver function, and evidence of an anti-fibrotic treatment effect, as well as rapid and sustained reductions in elevated levels of key biomarkers of inflammation and cell death, which play a role in the severity and progression of liver disease.
*About ENCORE-PH
*The randomized, double-blind ENCORE-PH Phase 2b clinical trial, initiated in the fourth quarter of 2016, enrolled 263 NASH patients with compensated or early decompensated liver cirrhosis and severe portal hypertension confirmed by HVPG of ≥12 mmHg at baseline. Patients were randomized 1:1:1:1 to receive 5 mg of emricasan, 25 mg of emricasan, 50 mg of emricasan, or placebo twice daily for 24 weeks. The trial was conducted at 75 U.S. and EU sites.
*About Emricasan Clinical Development
*ENCORE-PH is one of three randomized, double-blind, placebo-controlled Phase 2b clinical trials being conducted by Conatus in collaboration with Novartis, the EmricasaN, a Caspase inhibitOR, for Evaluation (ENCORE) trials, designed to evaluate emricasan in patients with fibrosis or cirrhosis caused by NASH. Extension of the ENCORE-PH trial as well as two additional ENCORE clinical trials are ongoing:
· ENCORE-PH (for Portal Hypertension) six-month extension, with 48-week liver function and clinical outcome results expected in mid-2019;
· ENCORE-NF (for NASH Fibrosis), initiated in the first quarter of 2016, in approximately 330 patients with NASH fibrosis, with top-line results expected in the first half of 2019; and· ENCORE-LF (for Liver Function), initiated in the second quarter of 2017, in approximately 210 patients with decompensated NASH cirrhosis, with top-line results expected in mid-2019.
*About Conatus Pharmaceuticals*
Conatus is a biotechnology company focused on the development of novel medicines to treat liver disease. In collaboration with Novartis, Conatus is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease. For additional information, please visit www.conatuspharma.com.
*Forward-Looking Statements**
*This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding: separate registration trials being needed in compensated and decompensated NASH cirrhosis; emricasan’s potential to provide clinical benefit; the timeline to announce results from the extension phase of the ENCORE-PH trial in mid-2019; the data from the ENCORE-PH, ENCORE-NF and ENCORE-LF trials warranting future discussions with regulatory authorities regarding pivotal trials; the timelines to announce results from the ongoing ENCORE clinical trials; and caspase inhibitors’ potential to interrupt the progression of a variety of diseases. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including: reported top-line results are based on preliminary analysis of key data and as a result, such top-line results may change following a more comprehensive review and may not accurately reflect the complete results of the clinical trial; Conatus’ ability to successfully enroll patients in and complete its ongoing clinical trials; Novartis continuing development and commercialization of emricasan; Conatus’ reliance on third parties to conduct its clinical trials, including the enrollment of patients, and manufacture its clinical drug supplies of emricasan; potential adverse side effects or other safety risks associated with emricasan that could delay or preclude its approval; results of future clinical trials of emricasan; and those risks described in Conatus’ prior press releases and in the periodic reports it files with the Securities and Exchange Commission. The events and circumstances reflected in Conatus’ forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, Conatus does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
^1 Berzigotti A et al. Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension. J Gastroenterol 2011. DOI: 10.1007/s00535-010-0360-z.
Turco L et al. Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis. J Hepatol 2018. DOI: 10.1016/j.jhep.2017.12.027.
*CONTACT:* Alan Engbring
Conatus Pharmaceuticals Inc.
(858) 376-2637
aengbring@conatuspharma.com Reported by GlobeNewswire 11 hours ago.
↧
Global HR Research Hires Veteran Sales Leader to Drive Growth
Global HR Research (GHRR), a leading provider of award-winning employment screening technology, data, and business analytics empowering clients with better background screening programs — today announced the strategic hiring of veteran executive sales leader Joseph Doyle.
FORT MYERS, Fla. (PRWEB) December 05, 2018
Global HR Research (https://www.ghrr.com/) — a leading provider of award-winning employment screening technology, data, and business analytics empowering clients with better background screening programs — today announced the strategic hiring of veteran executive sales leader Joseph Doyle (https://www.linkedin.com/in/joseph-doyle-67b9723/). “Joe is the perfect addition to our team of industry experts,” says GHRR President & CEO Brandon Phillips.
With the enlistment of Doyle - bringing 18 years of experience driving revenue growth and enhancing brand awareness for SaaS technology and employment screening companies - GHRR continues to build on its stellar reputation as an industry innovator.
“Joe’s expertise in major corporate transformations encompassing sales strategy, new client acquisition, sales processes, and client relationship management will, no doubt, blend seamlessly into our culture of providing the best solutions for our clients and partners,” says Phillips. “His innate understanding of the changing preferences of clients and constantly evolving and ever-critical trends has made him an expert in the industry.”
Doyle’s career accomplishments are well documented. Perhaps most notable, he helped transform background screening companies American Background and TalentWise into Top 10 and Top 5 global providers respectively, achieving 30-40% year over year organic sales growth. Other career highlights include preparing and leading corporate-wide sales efforts for market growth and brand capitalization with startup GoodHire, and veterans ESS and Applicant Insight.
In addition to achieving FRCA and Advanced FCRA certifications, Doyle has also held board positions with staffing associations and spoken at various conferences regarding compliance and best practices in background screening.
“I am confident Joe will help take GHRR to even greater heights as we continue to drive the development and delivery of advanced screening solutions to our clients as we grow in the coming years,” says Phillips.
About Global HR Research:
Global HR Research (https://ghrr.com/) combines advanced screening technology, data and business analytics to deliver better background screening programs to thousands of customers and their candidates. Serving small businesses to Fortune 500 companies across the country, Global HR Research –recognized for the past nine years in HRO Today Magazine’s “Bakers Dozen” List of top national background screening providers and by Workforce Magazine’s “Hot List” of top background screening providers for five of the past six years – is accredited by the National Association of Professional Background Screeners (NAPBS) as recognized by the Background Screening Credentialing Council (BSCC). Reported by PRWeb 11 hours ago.
FORT MYERS, Fla. (PRWEB) December 05, 2018
Global HR Research (https://www.ghrr.com/) — a leading provider of award-winning employment screening technology, data, and business analytics empowering clients with better background screening programs — today announced the strategic hiring of veteran executive sales leader Joseph Doyle (https://www.linkedin.com/in/joseph-doyle-67b9723/). “Joe is the perfect addition to our team of industry experts,” says GHRR President & CEO Brandon Phillips.
With the enlistment of Doyle - bringing 18 years of experience driving revenue growth and enhancing brand awareness for SaaS technology and employment screening companies - GHRR continues to build on its stellar reputation as an industry innovator.
“Joe’s expertise in major corporate transformations encompassing sales strategy, new client acquisition, sales processes, and client relationship management will, no doubt, blend seamlessly into our culture of providing the best solutions for our clients and partners,” says Phillips. “His innate understanding of the changing preferences of clients and constantly evolving and ever-critical trends has made him an expert in the industry.”
Doyle’s career accomplishments are well documented. Perhaps most notable, he helped transform background screening companies American Background and TalentWise into Top 10 and Top 5 global providers respectively, achieving 30-40% year over year organic sales growth. Other career highlights include preparing and leading corporate-wide sales efforts for market growth and brand capitalization with startup GoodHire, and veterans ESS and Applicant Insight.
In addition to achieving FRCA and Advanced FCRA certifications, Doyle has also held board positions with staffing associations and spoken at various conferences regarding compliance and best practices in background screening.
“I am confident Joe will help take GHRR to even greater heights as we continue to drive the development and delivery of advanced screening solutions to our clients as we grow in the coming years,” says Phillips.
About Global HR Research:
Global HR Research (https://ghrr.com/) combines advanced screening technology, data and business analytics to deliver better background screening programs to thousands of customers and their candidates. Serving small businesses to Fortune 500 companies across the country, Global HR Research –recognized for the past nine years in HRO Today Magazine’s “Bakers Dozen” List of top national background screening providers and by Workforce Magazine’s “Hot List” of top background screening providers for five of the past six years – is accredited by the National Association of Professional Background Screeners (NAPBS) as recognized by the Background Screening Credentialing Council (BSCC). Reported by PRWeb 11 hours ago.
↧
Eckrich® and Albertsons Team Up to Recognize Five Local Veterans at Dallas Mavericks Game
Smoked Sausage and Deli Meats Brand Surprises Local Heroes with $5,000 in Free Groceries
DALLAS, Dec. 05, 2018 (GLOBE NEWSWIRE) -- On Tuesday, Dec. 4, Eckrich^® took the court at the game between the Dallas Mavericks and the Portland Trail Blazers at American Airlines Center to surprise five former service members each with $1,000 in free groceries. This gift, presented in collaboration with grocery retailer Albertsons, is in recognition of the service and sacrifice of our nation’s military community.During a break in game action, Eckrich hosted a special on-court presentation where the brand commemorated the veterans with the special gift while thanking them for their service.
The five honorees served in varying branches of the military and are local to the Dallas community. Jeff Perkins served in the United States Coast Guard for 20 years. Edward Wimble served in the United States Army for 11 years. Mike Miller served in the United States Navy for 28 years. Brian Smith served in the United States Army for six years. Phillip Nguyen served in the United States Army for eight years.
“Eckrich has a long-standing pledge to support our nation’s armed forces for their service to our country,” said Michael Baughman, director of marketing for Smithfield Foods. “It’s rewarding to see the overwhelming warmth and appreciation in the Mavericks stadium tonight as Eckrich and Albertsons joined together to give thanks to these former service members for their brave contributions.”
Eckrich, the makers of naturally hardwood smoked sausage and perfectly seasoned deli meats, is proud to continue its ongoing commitment to honor, thank, and support active service members, veterans, and their families across the country. For more information about Eckrich, please visit www.eckrich.com or follow Eckrich on Facebook and Twitter. Eckrich is a brand of Smithfield Foods.
*About Eckrich*
The makers of naturally hardwood smoked sausage and savory deli meats, Eckrich was founded by Peter Eckrich in 1894 and has grown from a small meat market in Fort Wayne, Indiana, to one of the most recognized regional premium deli and meat brands on the market today. Through it all, Eckrich meats have been recognized for their great taste and supreme quality, craftsmanship, care, and pride. For more information, visit www.Eckrich.com. Eckrich is a brand of Smithfield Foods.
*About Smithfield Foods
*Smithfield Foods is a $15 billion global food company and the world's largest pork processor and hog producer. In the United States, the company is also the leader in numerous packaged meats categories with popular brands including Smithfield^®, Eckrich^®, Nathan’s Famous^®, Farmland^®, Armour^®, Farmer John^®, Kretschmar^®, John Morrell^®, Cook’s^®, Gwaltney^®, Carando^®, Margherita^®, Curly’s^®, Healthy Ones^®, Morliny^®, Krakus^®, and Berlinki^®. Smithfield Foods is committed to providing good food in a responsible way and maintains robust animal care, community involvement, employee safety, environmental, and food safety and quality programs. For more information, visit www.smithfieldfoods.com, and connect with us on Facebook, Twitter and LinkedIn.
*Media Contact*:
*Hunter PR for Eckrich*
Caroline Greer
cgreer@hunterpr.com
(212) 679-6600
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/707b377a-19cd-4b65-abdc-18a98c55c969 Reported by GlobeNewswire 8 hours ago.
DALLAS, Dec. 05, 2018 (GLOBE NEWSWIRE) -- On Tuesday, Dec. 4, Eckrich^® took the court at the game between the Dallas Mavericks and the Portland Trail Blazers at American Airlines Center to surprise five former service members each with $1,000 in free groceries. This gift, presented in collaboration with grocery retailer Albertsons, is in recognition of the service and sacrifice of our nation’s military community.During a break in game action, Eckrich hosted a special on-court presentation where the brand commemorated the veterans with the special gift while thanking them for their service.
The five honorees served in varying branches of the military and are local to the Dallas community. Jeff Perkins served in the United States Coast Guard for 20 years. Edward Wimble served in the United States Army for 11 years. Mike Miller served in the United States Navy for 28 years. Brian Smith served in the United States Army for six years. Phillip Nguyen served in the United States Army for eight years.
“Eckrich has a long-standing pledge to support our nation’s armed forces for their service to our country,” said Michael Baughman, director of marketing for Smithfield Foods. “It’s rewarding to see the overwhelming warmth and appreciation in the Mavericks stadium tonight as Eckrich and Albertsons joined together to give thanks to these former service members for their brave contributions.”
Eckrich, the makers of naturally hardwood smoked sausage and perfectly seasoned deli meats, is proud to continue its ongoing commitment to honor, thank, and support active service members, veterans, and their families across the country. For more information about Eckrich, please visit www.eckrich.com or follow Eckrich on Facebook and Twitter. Eckrich is a brand of Smithfield Foods.
*About Eckrich*
The makers of naturally hardwood smoked sausage and savory deli meats, Eckrich was founded by Peter Eckrich in 1894 and has grown from a small meat market in Fort Wayne, Indiana, to one of the most recognized regional premium deli and meat brands on the market today. Through it all, Eckrich meats have been recognized for their great taste and supreme quality, craftsmanship, care, and pride. For more information, visit www.Eckrich.com. Eckrich is a brand of Smithfield Foods.
*About Smithfield Foods
*Smithfield Foods is a $15 billion global food company and the world's largest pork processor and hog producer. In the United States, the company is also the leader in numerous packaged meats categories with popular brands including Smithfield^®, Eckrich^®, Nathan’s Famous^®, Farmland^®, Armour^®, Farmer John^®, Kretschmar^®, John Morrell^®, Cook’s^®, Gwaltney^®, Carando^®, Margherita^®, Curly’s^®, Healthy Ones^®, Morliny^®, Krakus^®, and Berlinki^®. Smithfield Foods is committed to providing good food in a responsible way and maintains robust animal care, community involvement, employee safety, environmental, and food safety and quality programs. For more information, visit www.smithfieldfoods.com, and connect with us on Facebook, Twitter and LinkedIn.
*Media Contact*:
*Hunter PR for Eckrich*
Caroline Greer
cgreer@hunterpr.com
(212) 679-6600
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/707b377a-19cd-4b65-abdc-18a98c55c969 Reported by GlobeNewswire 8 hours ago.
↧
DeAngelo Hall: On Vick’s Falcons, Why the Old Guys Don’t Last Anymore, and His Post-Retirement Plans to Do It All
He came into the league as a brash young shutdown corner and left as a veteran leader and elder statesman. One of the NFL’s most interesting players on the state of the game, aging in the NFL, why veterans don’t age like they used to, playing on the Michael Vick Falcons, player safety for his football-loving kids, and his retirement plans: basically, do it all
Reported by SI.com 7 hours ago.
↧
↧
Werner Enterprises Named a 2019 Military Friendly® Brand
OMAHA, Neb., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Werner Enterprises (NASDAQ: WERN), a premier transportation and logistics company, is honored to announce its designation as a 2019 Military Friendly^® Brand by VIQTORY.“We will continue our commitment to actively support all military service members, veterans, spouses and their families,” said President and Chief Executive Officer Derek Leathers. “Passion, dedication and adaptability are hallmarks of America’s military service members, and traits that we value at Werner.”
To be selected, organizations were evaluated using both public and government data sources with responses from a comprehensive survey completed by the employer. The Military Friendly^® Brand list provides a guide for veterans and their families using data sourced through a continuously improved methodology, criteria and weightings developed with the help of an independent research firm, and proprietary survey information from participating organizations.
As a military-friendly employer, Werner received the 2018 Secretary of Defense Employer Support Freedom Award, the highest recognition awarded by the Department of Defense, for its support of National Guard and Reserve members. Werner is proud that military veterans and veteran spouses comprise approximately 20 percent of its global workforce.
The 2019 Military Friendly^® Brands list will be published in the April issue of Military Spouse magazine and online.
Werner Enterprises, Inc. was founded in 1956 and is a premier transportation and logistics company, with coverage throughout North America, Asia, Europe, South America, Africa and Australia. Werner maintains its global headquarters in Omaha, Nebraska and maintains offices in the United States, Canada, Mexico and China. Werner is among the five largest truckload carriers in the United States, with a diversified portfolio of transportation services that includes dedicated; medium-to-long-haul, regional and expedited van; and temperature-controlled. The Werner Logistics portfolio includes truck brokerage, freight management, intermodal, international and final mile services. International services are provided through Werner’s domestic and global subsidiary companies and include ocean, air and ground transportation; freight forwarding; and customs brokerage.
Werner Enterprises, Inc.’s common stock trades on the NASDAQ Global Select Market^SM under the symbol “WERN.” For further information about Werner, visit the company’s website at www.werner.com.
Contact: Fred Thayer, Director of Corporate Communications
Werner Enterprises, Inc.
402.895.6640 ext. 100-2065
fthayer@werner.com Reported by GlobeNewswire 7 hours ago.
To be selected, organizations were evaluated using both public and government data sources with responses from a comprehensive survey completed by the employer. The Military Friendly^® Brand list provides a guide for veterans and their families using data sourced through a continuously improved methodology, criteria and weightings developed with the help of an independent research firm, and proprietary survey information from participating organizations.
As a military-friendly employer, Werner received the 2018 Secretary of Defense Employer Support Freedom Award, the highest recognition awarded by the Department of Defense, for its support of National Guard and Reserve members. Werner is proud that military veterans and veteran spouses comprise approximately 20 percent of its global workforce.
The 2019 Military Friendly^® Brands list will be published in the April issue of Military Spouse magazine and online.
Werner Enterprises, Inc. was founded in 1956 and is a premier transportation and logistics company, with coverage throughout North America, Asia, Europe, South America, Africa and Australia. Werner maintains its global headquarters in Omaha, Nebraska and maintains offices in the United States, Canada, Mexico and China. Werner is among the five largest truckload carriers in the United States, with a diversified portfolio of transportation services that includes dedicated; medium-to-long-haul, regional and expedited van; and temperature-controlled. The Werner Logistics portfolio includes truck brokerage, freight management, intermodal, international and final mile services. International services are provided through Werner’s domestic and global subsidiary companies and include ocean, air and ground transportation; freight forwarding; and customs brokerage.
Werner Enterprises, Inc.’s common stock trades on the NASDAQ Global Select Market^SM under the symbol “WERN.” For further information about Werner, visit the company’s website at www.werner.com.
Contact: Fred Thayer, Director of Corporate Communications
Werner Enterprises, Inc.
402.895.6640 ext. 100-2065
fthayer@werner.com Reported by GlobeNewswire 7 hours ago.
↧
People from all walks of life gather to honor George H.W. Bush
On Dec. 5, presidents, world envoys, veterans, and many more are gathering to honor the late former President George H.W. Bush, who passed away on Nov. 30. Mr. Bush is celebrated for his signing of the American with Disabilities Act in 1990, among a series of major accomplishments.
Reported by Christian Science Monitor 6 hours ago.
↧
A tiny startup wants to pay you for your DNA, and it could lead to the next wave of medical innovation
· A startup called LunaDNA is taking a new approach to genetic research by paying individuals to share their information with scientists.· Right now, some DNA testing companies already sell your genome for medical research, though you can usually opt out.
· You probably won't get rich off your DNA. LunaDNA estimates the value of your whole genome at $21, for now.
More and more, researchers are studying individuals' genetic information to find new medical treatments.
But a big challenge has been collecting enough information from enough people to find new cures. A startup called LunaDNA is pioneering a new approach, offering to pay people for their DNA and other health information.
Individuals will get shares of LunaDNA for providing their genetic data, as well as for activities like uploading their medical records or keeping track of what they eat and how much they work out. The idea is that the more someone participates, the more stock they'll accumulate, and the more they'll be rewarded.
"The people we want to attract are looking to solve a problem together, to help get in the fight against disease," Dawn Barry, the company's president and a co-founder, said in a November interview. "It’s not so much how much money you want to get back — people are in it for the altruism."
DNA testing startups like 23andMe already sell your genetic information for medical research, though you can opt out. Unlike 23andMe, LunaDNA doesn't provide the genetic testing itself. Instead, users can upload their files from companies like 23andMe.
The venture is just getting started. LunaDNA has raised $4 million and employs 12 people. The US Securities and Exchange Commission signed off this week on LunaDNA's plans to give individuals stock, and the company's web portal where users can upload their info opened on Wednesday.
LunaDNA wants to give you more control over how your data is used, and directly compensate you for sharing more. The company will provide aggregated data to researchers with identifying information removed, and only with the consent of the individuals involved. Members can delete their data from the platform at any time.
*Read more: DNA-testing company 23andMe has signed a $300 million deal with a drug giant. Here's how to delete your data if that freaks you out.*
"When value is created, it’s not all kept by the institution," Barry said in a December interview. "It’s actually distributed back to the community."You probably won't get rich by selling your genetic information. Unlike stock in a company, the shares that LunaDNA is giving its users don't have a monetary value and can't be bought or sold. Instead, they'll give users regular payouts when LunaDNA starts making money.
*Read more: I've taken AncestryDNA, 23andMe, and National Geographic genetics tests — here's how to choose one to try*
The company estimates the value of a user's whole genome at $21, or 300 shares. It'll give you 2 shares, worth 14 cents, for 20 days of nutrition or fitness data. As more users sign on to the site, and more researchers begin using it, the goal is for those values to increase, Barry said.
LunaDNA was founded in October 2017 by veterans of the DNA sequencing company Illumina, and counts Illumina Ventures among its backers. Barry, 44, worked at Illumina for a dozen years and CEO Bob Kain, 57, was an Illumina employee for 15 years. The third co-founder, chief finance officer David Lewis, 47, previously worked at an investment company.
· *Read more:*
*23andMe is getting serious about drug development — and it could signal a fresh approach to finding new medicines*
*Regulators just gave DNA-testing startup 23andMe the go-ahead to offer a health product that scientists have called dubious*
*Google's life-extension spinoff teamed up with Ancestry to study 54 million family trees — and learned that a surprising factor helps determine how long we live*
*I tried a test that let me peek inside my microbiome, the 'forgotten organ' that scientists say is the future of medicine — and what I learned shocked me*
Join the conversation about this story »
NOW WATCH: There's so much CO2 in the atmosphere that planting trees can no longer save us Reported by Business Insider 6 hours ago.
↧
New Vitae Co-Founder Reappointed to Philadelphia Mayor’s Commission on People with Disabilities
Adam Devlin will help shape policies that foster inclusion of those with disabilities
LIMEPORT, Pa. (PRWEB) December 05, 2018
Adam Devlin, co-founder and owner of New Vitae Wellness and Recovery, has been reappointed to serve on Philadelphia Mayor James F. Kenney’s Commission on People with Disabilities. The commission focuses on creating policies that support inclusion of those who identify with a cognitive or physical disability. Devlin serves as the chair of the Behavioral Health Committee to emphasize hope, recovery, and equality for the Philadelphia community.
“I am honored to serve the City of Philadelphia on this commission,” said Devlin. “I look forward to continuing our commitment to the community and support individuals across the city who experience cognitive and physical challenges.”
In the past year, the committee has successfully initiated a “call now” program for people who are homeless and have behavioral health challenges. Philadelphia libraries, churches, food banks, homeless shelters, and government agencies use the program to connect people in need with the appropriate resources.
The commission emphasizes accessibility and inclusion for individuals living with disabilities. The mayor’s office estimates that approximately 16 percent of all Philadelphians are affected by a cognitive or physical disability. The Mayor’s Commission on People with Disabilities provides a means for affected people to share concerns and work toward positive change in areas including housing, transportation, employment, and access to services.
New Vitae Wellness and Recovery serves the Philadelphia community with three Residential Treatment Facilities for Adults (RTFAs). These specialty programs were designed in conjunction with the City of Philadelphia Department of Behavioral Health, Community Behavioral Health, and the Beck Institute of the University of Pennsylvania. The programs are designed to help individuals utilize a holistic model of care to manage significant behavioral health symptoms and return to their families and communities.
Devlin will continue sharing his experience of more than 30 years in the field of behavioral health supports to be able to advise the mayor with respect to existing and proposed programs that provide services to those in need in the Philadelphia community.
About New Vitae Wellness and Recovery: New Vitae Wellness and Recovery offers a variety of behavioral health outpatient services, co-occurring addiction services, brain injury supports, and residential treatment facilities for adults. Emphasizing integrated and holistic healing options, all services are provided using the lens of the recovery model to ensure trauma-informed, strengths-based support. Our innovative, intensive care models blend clinical services with residential assistance to promote individualized wellness. New Vitae offers a continuum of housing options to maintain connections with local communities. We offer treatment tailored to the unique needs of individuals, including: veterans, young adults ages 18 to 25, and, through our Action Recovery services, individuals diagnosed with brain injuries, Autism Spectrum Disorders, or Intellectual DisAbilities. Our specialized services include Certified Peer Support, deep Transcranial Magnetic Stimulation, and Mobile Psychiatric Rehabilitation Services. To learn more, please visit http://www.newvitaewellness.com.
# # # Reported by PRWeb 5 hours ago.
LIMEPORT, Pa. (PRWEB) December 05, 2018
Adam Devlin, co-founder and owner of New Vitae Wellness and Recovery, has been reappointed to serve on Philadelphia Mayor James F. Kenney’s Commission on People with Disabilities. The commission focuses on creating policies that support inclusion of those who identify with a cognitive or physical disability. Devlin serves as the chair of the Behavioral Health Committee to emphasize hope, recovery, and equality for the Philadelphia community.
“I am honored to serve the City of Philadelphia on this commission,” said Devlin. “I look forward to continuing our commitment to the community and support individuals across the city who experience cognitive and physical challenges.”
In the past year, the committee has successfully initiated a “call now” program for people who are homeless and have behavioral health challenges. Philadelphia libraries, churches, food banks, homeless shelters, and government agencies use the program to connect people in need with the appropriate resources.
The commission emphasizes accessibility and inclusion for individuals living with disabilities. The mayor’s office estimates that approximately 16 percent of all Philadelphians are affected by a cognitive or physical disability. The Mayor’s Commission on People with Disabilities provides a means for affected people to share concerns and work toward positive change in areas including housing, transportation, employment, and access to services.
New Vitae Wellness and Recovery serves the Philadelphia community with three Residential Treatment Facilities for Adults (RTFAs). These specialty programs were designed in conjunction with the City of Philadelphia Department of Behavioral Health, Community Behavioral Health, and the Beck Institute of the University of Pennsylvania. The programs are designed to help individuals utilize a holistic model of care to manage significant behavioral health symptoms and return to their families and communities.
Devlin will continue sharing his experience of more than 30 years in the field of behavioral health supports to be able to advise the mayor with respect to existing and proposed programs that provide services to those in need in the Philadelphia community.
About New Vitae Wellness and Recovery: New Vitae Wellness and Recovery offers a variety of behavioral health outpatient services, co-occurring addiction services, brain injury supports, and residential treatment facilities for adults. Emphasizing integrated and holistic healing options, all services are provided using the lens of the recovery model to ensure trauma-informed, strengths-based support. Our innovative, intensive care models blend clinical services with residential assistance to promote individualized wellness. New Vitae offers a continuum of housing options to maintain connections with local communities. We offer treatment tailored to the unique needs of individuals, including: veterans, young adults ages 18 to 25, and, through our Action Recovery services, individuals diagnosed with brain injuries, Autism Spectrum Disorders, or Intellectual DisAbilities. Our specialized services include Certified Peer Support, deep Transcranial Magnetic Stimulation, and Mobile Psychiatric Rehabilitation Services. To learn more, please visit http://www.newvitaewellness.com.
# # # Reported by PRWeb 5 hours ago.
↧
↧
Sarah Palin’s son checks into Alaska halfway house
ANCHORAGE, Alaska (AP) — The oldest son of former Alaska Gov. Sarah Palin checked in to an Anchorage halfway house Wednesday to begin a year in custody following his conviction for assaulting his father. Track Palin was initially scheduled to enter the halfway house Oct. 31 after new assault allegations disqualified him from a veterans […]
Reported by Seattle Times 4 hours ago.
↧
Ramsey's Diamond Jewelers Opens Largest Diamond Store in Louisiana
Ramsey Family Celebrates 60th Year with the Grand Opening of Largest Diamond Store in Louisiana
METAIRIE, La. (PRWEB) December 05, 2018
The doors have opened to the largest diamond store in Louisiana – Ramsey’s Diamond Jewelers at 701 Veterans Blvd in Metairie – just in time for engagement season and holiday shopping. The brand new 8,400-square-foot beautiful retail space highlights more than 50 showcases of diamond jewelry in excess of 2,000 engagement and wedding rings, a state-of-the-art gem lab, a custom design studio, an observable service center, 44 parking spaces, and knowledgeable jewelry professionals. The official Grand Opening celebration was held on Wednesday, November 28th.
"When my father opened his little jewelry store 60 years ago, I doubt he ever dreamed it would grow to become Louisiana's largest diamond showroom," stated CEO Robert Ramsey, Jr. "But my sister Lori and I like to think that somewhere he is watching and smiling in approval."
The Ramsey family’s roots run deep in the Greater New Orleans area and the jewelry industry. Founded in 1958, Robert “Bob” Ramsey Sr. opened B & J Manufacturing Jewelers in New Orleans, manufacturing fine custom jewelry for other jewelers to sell under their own name. Bob decided to enter into the retail business in 1972 with the opening of Ramsey’s Jewelers in Metairie. Three years later, his son Robert Jr. joined the company as an apprentice jeweler, assuming control of operations with his sister Lori in 1980. Robert’s son Bobby joined Ramsey’s in 1999 after apprenticing with jewelry stores across the country.
“Life is about family and celebrations,” added Robert Ramsey Jr. “After 60 years in business, it was time to invest in our customers and community with our diamond superstore. We offer shoppers a convenient and relaxing atmosphere during the holiday shopping frenzy and engagement season.”
According to WeddingWire.com, 40 percent of couples get engaged between November and February. Ramsey’s knowledgeable staff caters to future newlyweds, providing them with personal diamond selection consultation, best price and grading guarantees, and affordable financing.
Whether visitors are looking for a private consultation or “wide open” showcases where merchandise can be tried on unassisted, the Ramsey’s shopping experience is like no other store in the state. The public is invited to visit Ramsey’s Diamond Jewelers at 701 Veterans Blvd in Metairie between Bonnabel Blvd and the parish line. Grand opening sale items will be featured the entire month of December. Follow Ramsey’s on social media for information on prize registrations.
About Ramsey’s Diamond Jewelers
Founded in 1958, Ramsey’s is now a 3rd generation jeweler celebrating 60 years as one of New Orleans’ best known businesses.
Many local New Orleanians grew up listening to Robert and Lori’s colorful radio commercials and instantly recognize the “Rrrrrrrrrramsey’s Diamond Jewelers” tagline when they hear it. "My friend Roy claims he's just been doing a bad imitation of Tony the Tiger for the past 25 years," says Robert Ramsey Jr., "but everyone from New Orleans who meets him asks him to do it for them, and he never lets them down."
Ramsey’s has a second location on the Westbank at 1901 Manhattan Blvd in Harvey that will soon be merged into the BIG store at 701 Veterans. For more information contact Robert Ramsey at 504-885-4653 or visit ramseys.com on the web. Follow us on Facebook. Reported by PRWeb 4 hours ago.
METAIRIE, La. (PRWEB) December 05, 2018
The doors have opened to the largest diamond store in Louisiana – Ramsey’s Diamond Jewelers at 701 Veterans Blvd in Metairie – just in time for engagement season and holiday shopping. The brand new 8,400-square-foot beautiful retail space highlights more than 50 showcases of diamond jewelry in excess of 2,000 engagement and wedding rings, a state-of-the-art gem lab, a custom design studio, an observable service center, 44 parking spaces, and knowledgeable jewelry professionals. The official Grand Opening celebration was held on Wednesday, November 28th.
"When my father opened his little jewelry store 60 years ago, I doubt he ever dreamed it would grow to become Louisiana's largest diamond showroom," stated CEO Robert Ramsey, Jr. "But my sister Lori and I like to think that somewhere he is watching and smiling in approval."
The Ramsey family’s roots run deep in the Greater New Orleans area and the jewelry industry. Founded in 1958, Robert “Bob” Ramsey Sr. opened B & J Manufacturing Jewelers in New Orleans, manufacturing fine custom jewelry for other jewelers to sell under their own name. Bob decided to enter into the retail business in 1972 with the opening of Ramsey’s Jewelers in Metairie. Three years later, his son Robert Jr. joined the company as an apprentice jeweler, assuming control of operations with his sister Lori in 1980. Robert’s son Bobby joined Ramsey’s in 1999 after apprenticing with jewelry stores across the country.
“Life is about family and celebrations,” added Robert Ramsey Jr. “After 60 years in business, it was time to invest in our customers and community with our diamond superstore. We offer shoppers a convenient and relaxing atmosphere during the holiday shopping frenzy and engagement season.”
According to WeddingWire.com, 40 percent of couples get engaged between November and February. Ramsey’s knowledgeable staff caters to future newlyweds, providing them with personal diamond selection consultation, best price and grading guarantees, and affordable financing.
Whether visitors are looking for a private consultation or “wide open” showcases where merchandise can be tried on unassisted, the Ramsey’s shopping experience is like no other store in the state. The public is invited to visit Ramsey’s Diamond Jewelers at 701 Veterans Blvd in Metairie between Bonnabel Blvd and the parish line. Grand opening sale items will be featured the entire month of December. Follow Ramsey’s on social media for information on prize registrations.
About Ramsey’s Diamond Jewelers
Founded in 1958, Ramsey’s is now a 3rd generation jeweler celebrating 60 years as one of New Orleans’ best known businesses.
Many local New Orleanians grew up listening to Robert and Lori’s colorful radio commercials and instantly recognize the “Rrrrrrrrrramsey’s Diamond Jewelers” tagline when they hear it. "My friend Roy claims he's just been doing a bad imitation of Tony the Tiger for the past 25 years," says Robert Ramsey Jr., "but everyone from New Orleans who meets him asks him to do it for them, and he never lets them down."
Ramsey’s has a second location on the Westbank at 1901 Manhattan Blvd in Harvey that will soon be merged into the BIG store at 701 Veterans. For more information contact Robert Ramsey at 504-885-4653 or visit ramseys.com on the web. Follow us on Facebook. Reported by PRWeb 4 hours ago.
↧
National Veteran Organization to Kickoff Army/Navy Weekend with Black Tie Gala Honoring Veterans
To kickoff Army/Navy Weekend in Philadelphia, Travis Manion Foundation (TMF) will host the 7th annual “If Not Me, Then Who…” Gala at the historic Union League, on Thursday, December 6th, 2018.
PHILADELPHIA (PRWEB) December 05, 2018
To kickoff Army/Navy Weekend in Philadelphia, Travis Manion Foundation (TMF) will host the 7th annual “If Not Me, Then Who…” Gala at the historic Union League, on Thursday, December 6th, 2018. This black tie event, which is a national recognition of character and leadership, will have attendees from across the country who are being honored for their dedication to selfless service within their local communities and around the globe.
Some of the high profile and notable figures in attendance or being honored include:· Secretary Richard V. Spencer – Richard V. Spencer of Wyoming was sworn in as the 76th secretary of the Navy Aug. 3, 2017. Secretary Spencer will serve as a Guest Speaker for the evening.
· General Stanley McChrystal – General Stanley McChrystal is a retired U.S. Army four-star general, and the former commander of U.S. and International Security Assistance Forces (ISAF) Afghanistan and the former commander of the premier military counter-terrorism force, Joint Special Operations Command (JSOC). General McChrystal will serve as a Guest Speaker for the evening.
· Chris Hixon – a Navy veteran and the athletic director of Margerie Stoneman Douglas High School in Parkland, FL, who rushed toward an active shooter – and gave his life in pursuit of saving his students’ on February 14th, 2018. Chris’ son Thomas Hixon will posthumously accept the “If Not Me, Then Who…” Leadership Award on behalf of his late father.
· Jimmy White - Upon learning of Chris’ sacrifice, Jimmy White, a Navy veteran and Character Does Matter mentor with TMF in Philadelphia, opted to reach out to the hero's family. Jimmy has shared Chris Hixon’s story of bravery and character with thousands of students to inspire them to carry on his legacy of service to others in their own community. Jimmy will also be presented with the prestigious “If Not Me, Then Who…” Leadership Award.
· Rob Riggle – Actor/comedian/writer/producer/director Rob Riggle has been a staple in comedic films and television for more than 15 years, and is known for his memorable characters in comedy hits like “The Hangover” and “Step Brothers,” as well as his recent appeared in Warner Bros.’ war drama “12 Strong”. Rob is also a Marine veteran, and will serve as the Emcee of the 2018 “If Not Me, Then Who…” Gala.
· General Michael Linnington – CEO of Wounded Warrior Project who previously served as the Military Deputy to the Under Secretary of Defense (Personnel and Readiness) from 2013 to 2015, and retired from the U.S. Army as a Lieutenant General. He will be accepting the Community Leadership Award on behalf of Wounded Warrior Project.
The evening will begin with a VIP reception at 5:30pm, which will be open to the media, followed by the full program starting at 7:30pm. Top level sponsors for this inspirational evening include Boeing, Humana, Polen Capital, Johnson & Johnson, Goldman Sachs, and Penn Medicine.
Travis Manion Foundation will continue the recognition of our nation’s bravest heroes, in conjunction with the 119th Army vs. Navy Football Game, which will take place at Lincoln Financial Field in Philadelphia on Saturday December 8th. TMF is the largest Veteran Service Organization in the Philadelphia region, and will host a fully catered veterans tailgate, in partnership with Amazon Military, Drexel Hamilton, and Tito’s Handmade Vodka.
The tailgate will take place prior to the Army vs. Navy football game, in the “K” Parking lot of Lincoln Financial Field. TMF has also arranged for game tickets that will be provided to over 20 Gold Star family members and more than 70 veterans, and active duty wounded military members who will travel from Walter Reed Hospital in a luxury bus with police escort to the event. More than 300 total guests are expected to attend the tailgate, and the estimated arrival of the wounded veterans to the tailgate is 1:00pm in the “K” Parking lot.
About Travis Manion Foundation
Travis Manion Foundation (TMF) unites communities to strengthen America's national character by empowering veterans and families of fallen heroes to develop and lead future generations. In 2007, 1st Lt. Travis Manion (USMC) was killed in Iraq while saving his wounded teammates. Today, Travis' legacy lives on in the words he spoke before leaving for his final deployment, "If Not Me, Then Who..." Guided by this mantra, veterans continue their service, develop strong relationships with their communities, and thrive in their post-military lives by serving as character role models to youth. As a result, communities prosper and the character of our nation’s heroes lives on in the next generation.
The story of 1st Lt. Travis Manion and his Naval Academy brother Lt. (SEAL) Brendan Looney have been publicized in the book Brothers Forever, and additional information about the Foundation can be found at http://www.travismanion.org. Reported by PRWeb 3 hours ago.
PHILADELPHIA (PRWEB) December 05, 2018
To kickoff Army/Navy Weekend in Philadelphia, Travis Manion Foundation (TMF) will host the 7th annual “If Not Me, Then Who…” Gala at the historic Union League, on Thursday, December 6th, 2018. This black tie event, which is a national recognition of character and leadership, will have attendees from across the country who are being honored for their dedication to selfless service within their local communities and around the globe.
Some of the high profile and notable figures in attendance or being honored include:· Secretary Richard V. Spencer – Richard V. Spencer of Wyoming was sworn in as the 76th secretary of the Navy Aug. 3, 2017. Secretary Spencer will serve as a Guest Speaker for the evening.
· General Stanley McChrystal – General Stanley McChrystal is a retired U.S. Army four-star general, and the former commander of U.S. and International Security Assistance Forces (ISAF) Afghanistan and the former commander of the premier military counter-terrorism force, Joint Special Operations Command (JSOC). General McChrystal will serve as a Guest Speaker for the evening.
· Chris Hixon – a Navy veteran and the athletic director of Margerie Stoneman Douglas High School in Parkland, FL, who rushed toward an active shooter – and gave his life in pursuit of saving his students’ on February 14th, 2018. Chris’ son Thomas Hixon will posthumously accept the “If Not Me, Then Who…” Leadership Award on behalf of his late father.
· Jimmy White - Upon learning of Chris’ sacrifice, Jimmy White, a Navy veteran and Character Does Matter mentor with TMF in Philadelphia, opted to reach out to the hero's family. Jimmy has shared Chris Hixon’s story of bravery and character with thousands of students to inspire them to carry on his legacy of service to others in their own community. Jimmy will also be presented with the prestigious “If Not Me, Then Who…” Leadership Award.
· Rob Riggle – Actor/comedian/writer/producer/director Rob Riggle has been a staple in comedic films and television for more than 15 years, and is known for his memorable characters in comedy hits like “The Hangover” and “Step Brothers,” as well as his recent appeared in Warner Bros.’ war drama “12 Strong”. Rob is also a Marine veteran, and will serve as the Emcee of the 2018 “If Not Me, Then Who…” Gala.
· General Michael Linnington – CEO of Wounded Warrior Project who previously served as the Military Deputy to the Under Secretary of Defense (Personnel and Readiness) from 2013 to 2015, and retired from the U.S. Army as a Lieutenant General. He will be accepting the Community Leadership Award on behalf of Wounded Warrior Project.
The evening will begin with a VIP reception at 5:30pm, which will be open to the media, followed by the full program starting at 7:30pm. Top level sponsors for this inspirational evening include Boeing, Humana, Polen Capital, Johnson & Johnson, Goldman Sachs, and Penn Medicine.
Travis Manion Foundation will continue the recognition of our nation’s bravest heroes, in conjunction with the 119th Army vs. Navy Football Game, which will take place at Lincoln Financial Field in Philadelphia on Saturday December 8th. TMF is the largest Veteran Service Organization in the Philadelphia region, and will host a fully catered veterans tailgate, in partnership with Amazon Military, Drexel Hamilton, and Tito’s Handmade Vodka.
The tailgate will take place prior to the Army vs. Navy football game, in the “K” Parking lot of Lincoln Financial Field. TMF has also arranged for game tickets that will be provided to over 20 Gold Star family members and more than 70 veterans, and active duty wounded military members who will travel from Walter Reed Hospital in a luxury bus with police escort to the event. More than 300 total guests are expected to attend the tailgate, and the estimated arrival of the wounded veterans to the tailgate is 1:00pm in the “K” Parking lot.
About Travis Manion Foundation
Travis Manion Foundation (TMF) unites communities to strengthen America's national character by empowering veterans and families of fallen heroes to develop and lead future generations. In 2007, 1st Lt. Travis Manion (USMC) was killed in Iraq while saving his wounded teammates. Today, Travis' legacy lives on in the words he spoke before leaving for his final deployment, "If Not Me, Then Who..." Guided by this mantra, veterans continue their service, develop strong relationships with their communities, and thrive in their post-military lives by serving as character role models to youth. As a result, communities prosper and the character of our nation’s heroes lives on in the next generation.
The story of 1st Lt. Travis Manion and his Naval Academy brother Lt. (SEAL) Brendan Looney have been publicized in the book Brothers Forever, and additional information about the Foundation can be found at http://www.travismanion.org. Reported by PRWeb 3 hours ago.
↧
More Pages to Explore .....
